A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

NCT05812677 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Endometrial Cancer
Advanced Cancer

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]